Annabel Samimy
Stock Analyst at Stifel
(3.56)
# 869
Out of 5,084 analysts
49
Total ratings
48.94%
Success rate
37.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Maintains: Buy | $87 → $145 | $93.90 | +54.43% | 3 | Nov 24, 2025 | |
| GPCR Structure Therapeutics | Initiates: Buy | $50 | $32.85 | +52.21% | 1 | Jan 8, 2025 | |
| ALT Altimmune | Initiates: Buy | $18 | $5.31 | +238.98% | 1 | Jan 8, 2025 | |
| IVA Inventiva | Maintains: Buy | $20 → $17 | $4.13 | +311.62% | 4 | Nov 22, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $40 | $30.99 | +29.09% | 1 | Oct 8, 2024 | |
| KMDA Kamada | Initiates: Buy | $18 | $7.12 | +152.81% | 1 | Jul 3, 2024 | |
| PHAT Phathom Pharmaceuticals | Initiates: Buy | $24 | $14.64 | +63.93% | 1 | May 3, 2024 | |
| RGNX REGENXBIO | Maintains: Buy | $40 | $13.10 | +205.34% | 2 | Apr 12, 2024 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $80 | $38.86 | +105.87% | 6 | Mar 15, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $225 → $230 | $166.39 | +38.23% | 8 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 → $25 | $6.80 | +267.92% | 1 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $19.58 | +78.80% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $65 | $22.05 | +194.85% | 3 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $700 → $275 | $8.15 | +3,274.23% | 4 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $39.45 | +14.07% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.58 | +1,423.81% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $700 → $750 | $1.61 | +46,483.85% | 3 | Apr 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $25 → $24 | $44.86 | -46.50% | 7 | Apr 16, 2020 |
Palvella Therapeutics
Nov 24, 2025
Maintains: Buy
Price Target: $87 → $145
Current: $93.90
Upside: +54.43%
Structure Therapeutics
Jan 8, 2025
Initiates: Buy
Price Target: $50
Current: $32.85
Upside: +52.21%
Altimmune
Jan 8, 2025
Initiates: Buy
Price Target: $18
Current: $5.31
Upside: +238.98%
Inventiva
Nov 22, 2024
Maintains: Buy
Price Target: $20 → $17
Current: $4.13
Upside: +311.62%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $40
Current: $30.99
Upside: +29.09%
Kamada
Jul 3, 2024
Initiates: Buy
Price Target: $18
Current: $7.12
Upside: +152.81%
Phathom Pharmaceuticals
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $14.64
Upside: +63.93%
REGENXBIO
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $13.10
Upside: +205.34%
Viking Therapeutics
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $38.86
Upside: +105.87%
Jazz Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $166.39
Upside: +38.23%
Mar 8, 2024
Reiterates: Buy
Price Target: $23 → $25
Current: $6.80
Upside: +267.92%
Oct 5, 2023
Initiates: Buy
Price Target: $35
Current: $19.58
Upside: +78.80%
Aug 29, 2023
Maintains: Buy
Price Target: $60 → $65
Current: $22.05
Upside: +194.85%
Jun 26, 2023
Downgrades: Hold
Price Target: $700 → $275
Current: $8.15
Upside: +3,274.23%
Mar 7, 2023
Initiates: Buy
Price Target: $45
Current: $39.45
Upside: +14.07%
Aug 24, 2021
Initiates: Buy
Price Target: $24
Current: $1.58
Upside: +1,423.81%
Apr 16, 2020
Maintains: Buy
Price Target: $700 → $750
Current: $1.61
Upside: +46,483.85%
Apr 16, 2020
Maintains: Hold
Price Target: $25 → $24
Current: $44.86
Upside: -46.50%